Isomorphic Labs, an AI drug development company led by Demis Hassabis and owned by Alphabet, is in early negotiations for a new funding round, with a valuation of at least $40 billion, potentially reaching $50 billion. The company completed a $2.1 billion Series B funding round in May of this year. Reports also indicate that the application of AI in the biopharmaceutical sector is still in its early stages, requiring more effort before reaching clinical trials and product launches. The negotiations are still in the early stages, and specific terms and investor information have not been disclosed.